Reno, Nevada--(ACN Newswire via SeaPRwire.com - February 25, 2026) - Executive Agility, a boutique consultancy specializing in IPO readiness, governance and multi-stakeholder project management for effective capital markets execution, today announced a strategic collaboration with DealMaker, a leading online capital-raising platform that powers online capital (ie: Regulation A) for emerging companies right through to IPO. The collaboration gives global growth and pre-IPO companies targeting listings on U.S. and Canadian stock exchanges - such as TSX, TSXV, CSE, U.S. national exchanges, SEC-registered offerings, and OTC markets - access to a self-directed, tech-enabled capital-raising channel that complements traditional investment banking and underwriting.A Digital, Self-Directed Capital-Raising Path that Complements Investment BanksThrough this collaboration, Executive Agility will integrate DealMaker's digital capital-raising infrastructure into its IPO readiness and governance services, enabling issuers to run online Regulation A, Regulation CF, and Regulation D campaigns while also working with investment banks and underwriters on traditional offerings. These exempt offerings can be sequenced before or alongside underwritten IPOs, uplists, or other SEC-registered transactions, allowing issuers to validate investor demand, build investor communities, and strengthen their capital structure ahead of a listing."IPO-bound and dual-listing companies want more control over their capital-raising journey while still leveraging the strengths of investment banks and underwriters," said Deb Banning, CEO and Founder of Executive Agility. "By combining Executive Agility's IPO readiness, governance benchmarking, and capital markets execution expertise with DealMaker's digital capital-raising platform, we provide issuers with a coordinated, complementary set of tools to raise capital, de-risk execution and move faster toward listing on U.S. and Canadian exchanges.""Our mission is to give founders and executives a digital, compliant way to raise capital on their own terms, from early growth through IPO," said Rebecca Kacaba, co-founder and CEO of DealMaker. "Working alongside Executive Agility's IPO readiness and governance advisory services - and within a broader ecosystem of global exchanges - we help issuers utilize flexible, compliant offerings in a way that perfectly complements traditional investment banking, rather than competing with it."Executive Agility Facilitates Cross-Border Capital Markets TransactionsExecutive Agility's IPO and listing readiness services routinely assist issuers pursuing listings, uplistings, or dual / cross-listings on the CSE, NSX and other North American and international exchanges, within integrated U.S.-Canada-Australia capital markets strategies.Executive Agility enables issuers to:Engage key capital markets participants to secure growth and pre-IPO funding for upcoming IPOs, RTOs, uplistings, and exchange transitions in the U.S. and Canada.Pursue dual listings, cross-listings, and uplistings on CSE, TSX / TSXV, U.S. exchanges, OTCQX / OTCQB, and NSXAAlign governance, disclosure, and execution with SEC, Canadian, and other regulatory standardsCoordinate governance benchmarking, disclosure readiness, and execution oversight to satisfy public-market requirements during capital raisingEnd-to-End IPO Readiness, Governance and Capital Markets ExecutionExecutive Agility operates as the execution and coordination layer between issuers, boards, underwriters, legal counsel, auditors, regulators, and other advisors, ensuring companies are not only technically eligible to list, but genuinely ready to operate as public companies. The firm's services include IPO and listing readiness assessments, governance benchmarking, disclosure and continuous reporting frameworks, multi-party stakeholder coordination, and leadership deployment to stabilize organizations during change and transactions.By adding DealMaker as a preferred digital raising platform within its curated Professional Network, Executive Agility now offers IPO readiness and capital-raising clients:A flexible, tech-driven capital-raising channel (Reg A, Reg CF, Reg D) that can be used pre-IPO, between rounds, and post-listing alongside underwritten offerings.Faster, more predictable IPO and listing timelines through structured project management, governance remediation, and integrated capital markets execution across U.S., Canadian, and cross-border markets.A coordinated, white-glove approach that reduces transaction and execution risk and improves the quality of filings and investor communications across the IPO and listing lifecycle.About Executive AgilityExecutive Agility serves as the strategic quarterback for the IPO and listing process, providing global growth companies with a rapid, coordinated and cost-effective path to market success. The firm specializes in IPO readiness, governance transformation and executive deployment for issuers targeting the TSX, TSXV, CSE, U.S. national exchanges and OTC markets.As the essential execution layer between issuers, boards, underwriters, legal counsel and regulators, Executive Agility ensures organizations are not only technically eligible to list but genuinely prepared to operate as sophisticated public companies. By integrating a turnkey professional network with modern digital capital-raising tools, we reduce transaction risk, accelerate timelines and reduce costs. Executive Agility empowers growth-stage companies to navigate the complexities of U.S., Canadian and cross-border capital markets with speed, institutional-grade discipline and confidence.About DealMakerHeadquartered in New York City, DealMaker is the future of capital raising. With more than $2.4 billion raised, DealMaker's platform enables companies to own their end-to-end capital raising lifecycle—from investor acquisition and conversion to compliance, payments, and engagement. Its white-label approach allows companies to retain ownership of their data and investor relationships while building lasting investor communities around their brands. For more information, visit dealmaker.tech.Media Contact - Executive AgilityDeb BanningChief Executive Officerinfo@executive-agility.comMedia Contact - DealMakerChris DeLucapress@dealmaker.techTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/285279 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Resource estimate highlights:Measured Mineral Resources of 272 million tonnes (Mt), Indicated Mineral Resources of 337 Mt, and Inferred Mineral Resources of 503 Mt at a 0.2% copper equivalent (CuEq) cut-off grade, or272 Mt of Measured Mineral Resources, expressed in contained metal, total 2.61 billion pounds (Blb) of copper equivalent (CuEq) at 0.44% CuEq, including 1.11 Blb of copper, 35.6 million pounds (Mlb) of cobalt, 1.41 million ounces (Moz) of gold, and 2.17 Moz of silver. (Table 1)337 Mt of Indicated Mineral Resources, expressed in contained metal, total 3.21 Blb of 0.43% CuEq, including 1.31 Blb of copper, 44.5 Mlb of cobalt, 1.81 Moz of gold, and 2.88 Moz of silver. (Table 1)509 Mt of Inferred Mineral Resources, expressed in contained metal, total 4.57 Blb of 0.41% CuEq, including 1.72 Blb of copper, 66.2 Mlb of cobalt, 2.77 Moz of gold, and 4.19 Moz of silver. (Table 1)Scandium Resource: The deposit hosts 609 Mt in the Measured and Indicated categories (containing approximately 17,510 tonnes of scandium) and 504 Mt in the Inferred category (containing approximately 14,465 tonnes of scandium). Scandium has been incorporated into the Mineral Resource Estimate and under current processing constraints, is limited to 12.5% of tailings using internally generated acid. The scandium resource is estimated at 76 Mt Measured and Indicated at 28.8 g/t Sc (containing 2,189 tonnes of scandium) and 63 Mt Inferred at 28.7 g/t Sc (containing 1,808 tonnes of scandium).Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 25, 2026) - Doubleview Gold Corp (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce the update of the Mineral Resource estimate (MRE) of its 100%-owned polymetallic Hat porphyry project (Hat), in northwestern British Columbia. With major content of copper, gold, cobalt and silver, as well as scandium, Hat becomes an important source of critical minerals.Farshad Shirvani, president and CEO of Doubleview Gold Corp commented, "Year by year, the size of the deposit was increased by very targeted drilling, bringing it to a footprint of about 1.6 km by 1.6 km. I appreciate my technical and management team in this endeavour. We've discovered numerous additional elements within the Hat deposit that will soon be unveiled, each further showcasing the deposit's uniqueness and enhancing the resource."Summary of MRE for Hat Deposit:Table 1: Hat MRE at a 0.2% CuEq Cut-Off Effective February 4, 2026,(Base-Case Scenario to be Presented in the Technical Report)Mineral Resource ClassificationTonnage(Mt)Average GradeMetal ContentCuEq(%)Cu(%)Au(g/t)Co(%)Ag(g/t)CuEq(Blb)Cu(Blb)Au(Moz)Co(Mlb)Ag(Moz)Measured2720.440.220.180.0080.372.611.111.4135.62.17Indicated3370.430.210.190.0080.393.211.311.8144.52.88Total M+I6090.430.210.180.0080.385.822.423.2280.15.05Inferred5030.410.180.190.0080.384.571.722.7766.24.19 Table 2: Hat MRE at a 0.2% CuEq Cut-Off as of February 4, 2026, Scandium Oxide ResourcesMineral Resource ClassificationTonnage(Mt)Sc Tonnage1(Mt)Average GradeSc (g/t)Metal ContentSc2O3 2 (t)Measured2723428.791,081Indicated3374228.761,334Total M+I6097628.772,415Inferred5036328.691,996 Notes: 1 Scandium tonnages represent 12.5% of the mineralized material by category, reflecting the proportion of tailings expected to be processed through a dedicated scandium leach circuit under current metallurgical design constraints.2 Scandium oxide metal content have been calculated using the metallurgical recovery of 72% and conversion factor from Sc to Sc2O3 of 1.534. Mineit's Qualified Person, Tomasz Wawruch, FAusIMM, completed the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a senior geology and mineral resource consultant independent of Doubleview. Mr. Gilles Arseneau, PhD., P.Geo., of ARSENEAU Consulting Services Inc., provided an independent review of this MRE.Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.Inferred Mineral Resources are considered too speculative geologically to have economic considerations applied to them that would enable them to be categorized as Mineral Reserves. The Mineral Resource Estimate was prepared in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") Definition Standards for Mineral Resources and Mineral Reserves (2014), and CIM MRMR Best Practice Guidelines (2019).The effective date of the MRE is February 4, 2026.Metal contents have been calculated using the following metallurgical recovery factors: Cu = 85%, Au = 89%, Co = 78%, and Ag = 68%.Economic assumptions used include US$4.80/lb Cu, US$20.00/lb Co, US$3,200/oz Au, US$46/oz Ag, and a 2% NSR royalty.Mineral Resources are reported within optimized open pit constraints and 0.2% CuEq cut-off grade, based on a C$7.93/t milled processing cost and C$2.90/t milled general and administrative cost, with a mining cost of C$3.01/t plus incremental mining cost increasing by C$0.015/t for every bench below the reference level of 1,125 mRL.CuEq calculations do not include scandium. The formula used to calculate CuEq is: CuEq = [(((Ag × 46.0 × 0.68)/31.1035) + ((Au × 3200 × 0.89)/31.1035) + 0.0001 × (Co × 20.0 × 0.78 × 22.0462) + 0.0001 × (Cu × 4.8 × 22.0462 × 0.85))/(4.8 × 22.0462 × 0.85)], where all input variables are expressed in (ppm) and CuEq is expressed in percent (%).Rounding may result in minor variations between individual values and totals; such differences are not considered material to the MRE.Mineral Resource classification reflects the level of geological confidence and satisfies the uncertainty criteria appropriate for exploration and resource development. Additional drilling will be required to reduce uncertainty to the level expected for production planning. The MRE reflects the geological interpretation, drill-hole spacing, and estimation parameters available at the time of modelling. Any additional drilling is expected to influence the current outcome by improving confidence in the estimates and refining the geometry of the mineralized domains.The Mineral Resource results are presented in situ within the optimized pit. Mineralized material outside the pit has not been considered as a part of the current MRE tabulation. Calculations used metric units (metres, tonnes, g/t).A total of 97 diamond drill holes, comprising 49,548 m of core, were incorporated into the Mineral Resource Estimate. All drilling data used in the MRE were subject to standard QA/QC validation prior to inclusion.The block model is defined relative to a model origin at UTM Zone 9N 346,750 E / 6,453,000 N / 0 (NAD 83). Parent blocks measure 15 × 15 × 15 m, totalling 136 × 150 × 75 blocks across extents of 2,040 m (X), 2,250 m (Y), and 1,125 m (Z). All volumes and estimates are constrained by these discretization parameters. Figure 1: Plan View at 715 m ASL of the Block Model Showing the Distribution of Equivalent Copper Grade Within the Optimized 120 Kilotonne per Day (kt/d) Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_001full.jpgFigure 2: Cross-Section of East 348000 Looking West of the Block Model Showing the Distribution of Equivalent Copper Grade Within the Optimized 120 kt/d Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_002full.jpgFigure 3: Plan View at 715 m ASL of the Block Model Showing the Distribution of Equivalent Copper Classification Within the 120 kt/d Optimized Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_003full.jpgFigure 4: Cross-Section of East 348000 Looking West of the Block Model Showing the Distribution of Equivalent Copper Classification Within the 120 kt/d Optimized Pit Shell Outline (UTM Zone 9N [NAD 83])To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/285247_b57c38042424daa0_004full.jpgThe Hat DepositThe Hat Claims property consists of 16 mineral tenures covering 13,823.09 hectares north of the Golden Bear mine road in northwest B.C. For additional information please visit www.doubleview.ca.Mineit Consulting Inc (Mineit) prepared the MRE in accordance with CIM Definition Standards on Mineral Resources and Reserves on Mineral Resources and Reserves. A Technical Report in support of the MRE will be filed on SEDAR+ (www.sedarplus.ca) within 45 days.Tomasz Wawruch, FAusIMM, of Mineit, is the Qualified Person for the MRE, and has reviewed and approved the technical disclosure related to the MRE contained in this news release. Mr. Wawruch is a geology and mineral resource consultant independent of Doubleview. Gilles Arseneau, PhD., P.Geo of ARSENEAU Consulting Services Inc. provided an independent peer review of the MRE and did not identify any fatal flaws with the resource model prepared by Tomasz Wawruch.With respect to the Hat Project metallurgical studies, EUR ING Andrew Carter, B.Sc., CEng., MIMMM QMR, MSAIMM SME, of Magister Metallurgy, is Doubleview's Qualified Person, as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects; he has reviewed and approved the technical contents of this news release. Mr. Carter is independent of Doubleview.About Doubleview Gold Corp.Doubleview Gold Corp., a mineral resource exploration and development company based in Vancouver, British Columbia, Canada, is publicly traded on the TSX-Venture Exchange (TSXV: DBG), the OTCQB (OTCQB: DBLVF), the Berlin Stock Exchange [GER: A1W038], and the Frankfurt Stock Exchange [1D4]. Doubleview identifies, acquires, and finances precious and base metal exploration projects in North America, particularly in British Columbia. The Company increases shareholder value through the acquisition and exploration of quality gold, copper, cobalt, scandium, and silver properties—collectively critical minerals—and through the application of advanced, state-of-the-art exploration methods. Doubleview's portfolio of strategic properties provides diversification and mitigates investment risk.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold CorpVancouver, BCFarshad ShirvaniPresident & CEOInstitutional Line: (604) 607-5470T: (604) 678-9587E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the Mineral Resource Estimate and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285247 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀有限公司（1952.HK）宣布，于2026年2月24日以线上虚拟会议形式举行的股东特别大会顺利召开，会议所提呈的全部决议案均获股东正式通过。根据公告，本次股东特别大会批准、确认及追认了公司于2025年12月11日与海森生物签署的商业化服务协议及其项下拟进行的相关交易，为公司后续商业化运营及业务推进提供支持。与此同时，大会还批准了向公司管理层授出奖励安排，以及采纳2026年股份计划及相关授权限额等决议案。此次各项决议案的高票通过，体现了投资者对公司战略方向及公司治理的认可，并将支持公司持续推进商业化布局及长期发展战略。云顶新耀此前表示，与海森生物的合作有助于进一步提升现有商业化平台运营效率，加快产品全生命周期及全渠道覆盖能力建设。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
- Exhibition space fully secured prior to the show, reflecting strong exhibitor confidence in Northern Vietnam’s laboratory and scientific markets- Over 150 international and local exhibitors & brands confirmed from USA, Germany, Japan, Korea, Taiwan, Singapore, Switzerland, France, India, Vietnam and China & more- Expanded Live Lab, following its debut in Ho Chi Minh 2025, now making its first appearance in HanoiHANOI, Vietnam, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) - analytica Hanoi 2026, the regional edition of the globally recognised analytica brand, will take place from 22–24 April 2026 at the International Centre of Exhibition (I.C.E), Hanoi. Tailored to the needs of Northern Vietnam's science and laboratory community, the exhibition space is fully secured ahead of opening, reflecting strong market demand and the growing importance of Vietnam as a laboratory and innovation hub."Northern Vietnam is rapidly emerging as a hub for laboratory innovation. With analytica Hanoi 2026, we are bringing the Live Lab to Hanoi for the first time, following its successful debut in Ho Chi Minh 2025. This demonstrates our commitment to connecting international solution providers with the region’s growing scientific and industrial community," said Michael Wilton, CEO and Managing Director, Messe Muenchen International Asia Pte, Ltd.Broad International Participation Reflects Market Relevanceanalytica Hanoi 2026 will feature over 150 exhibitors and brands from key laboratory and technology markets including USA, Germany, Japan, Korea, Taiwan, Singapore, Switzerland, France, India, Vietnam, Latvia, China etc. highlighting its strong global reach. This edition builds on the success of previous analytica Vietnam shows, offering a dedicated platform for technology exchange, business networking and market access tailored to Northern Vietnam.The exhibition will showcase laboratory instruments, analytical systems, biotechnology and diagnostics solutions, quality assurance technologies, and sustainable laboratory operations, meeting the evolving needs of the region’s laboratory and research sectors.Live Lab Makes Its Northern DebutFollowing its successful debut at analytica Vietnam Ho Chi Minh 2025, the Live Lab is coming to Hanoi for the first time in 2026. This interactive zone allows exhibitors to present hands-on demonstrations of laboratory technologies and real-world applications, enabling visitors to directly experience workflows, assess performance, and explore practical solutions.By bringing this pioneering format to Northern Vietnam, analytica Hanoi 2026 provides a first-of-its-kind experiential platform in Hanoi, offering laboratory professionals, researchers, and industrial users a unique opportunity to engage with both international and local technology providers in a practical, applied setting.Northern Vietnam Strengthens Its Role as a Growth MarketNorthern Vietnam is a key driver of Vietnam’s science and technology-led industrial upgrading, with strong investment across pharmaceuticals, healthcare, electronics, food safety, environmental monitoring, and advanced manufacturing. These sectors underpin national priorities on innovation, quality infrastructure, and sustainable growth, increasing demand for advanced laboratory technologies and digitalised operations.Building on this momentum, analytica Hanoi 2026 supports national science & technology objectives as a platform for knowledge exchange, standards alignment, and technology adoption.The event features a two-stage programme. The Academic Conference, jointly organised by Messe München, the Vietnam Analytical Sciences Society (VASS), VNU University of Science (HUS) – Vietnam National University, and VNEES, contributes to knowledge advancement and talent development in priority fields including green and environmental chemistry, food safety and quality control, semiconductor manufacturing, and molecular biology applications in biopharma and pharmacogenomics. The Technical Forum reinforces quality infrastructure and regulatory readiness, addressing ISO/IEC 17025, GLP, the laboratory outlook for 2026–2030, and applied seminars, complemented by exhibitor technology sessions.A Trusted Platform for Business and KnowledgeThe full occupancy of exhibition space underscores analytica Hanoi’s role as a reliable platform linking global technology providers with Northern Vietnam’s laboratory and research community. Confirmed exhibitors include WESTINGAREA, WIGGENS, GL SCIENCES, BCE, CHC LAB, DAIHAN SCIENTIFIC, ANTON PAAR, KIMTECO, LECO VIETNAM, GLASS TAO, FOSS VIETNAM, HTI SCIENTIFIC, MERCK VIETNAM, UNITEK and many more.Supporting programmes such as live demonstrations, hosted buyer engagements, and structured business matching further enhance opportunities for business development and collaboration.REGISTRATION NOW OPENanalytica Hanoi 2026 is expected to attract laboratory professionals, researchers, manufacturers, distributors, and institutional representatives from across Vietnam and the region.Visitor registration is now open:https://registration.analyticavietnam.com.vn/en/reg/analytica-vietnamFor more information, please visit www.analyticavietnam.comor contact analytica Vietnam via email analyticavietnam@mmiasia.com.sgAbout analytica Hanoi 2026analytica Hanoi is the official regional spinoff of analytica Vietnam, strategically developed to meet the rising demand for laboratory and analytical solutions in northern Vietnam. As the region experiences accelerated growth in research, healthcare, and industrial sectors, analytica Hanoi 2026 offers a focused platform for companies aiming to tap into this dynamic and fast-emerging market. The upcoming exhibition is set to take place from April 22 to 24, 2026 at the International Centre of Exhibition (I.C.E), 91 Tran Hung Dao, Hanoi, Vietnam.About analytica Vietnam 2027analytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies, exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from March 31 to April 2, 2027 at the Saigon Exhibition and Convention Center (SECC), 799 Nguyen Van Linh, Ho Chi Minh City, Vietnam. More details can be found here.About analytica worldwideFor over five decades, analytica has been the leading international trade fair series for laboratory technology, analysis, and biotechnology. Organized by Messe München, the series includes analytica in Munich, analytica China, analytica Anacon India, analytica USA, analytica Vietnam, and now, analytica Hanoi. Additional information about these exhibitions and their programs of events is available at www.analytica.de.About MMI Asia Pte LtdEstablished in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of world-leading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.com.About Messe MünchenAs one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twe lve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.Exhibition Contact:MMI Asia Pte. Ltd.Siegli L. BacudioProject Managersiegli@mmiasia.com.sgPress Contact:MMI Asia Pte. Ltd.Shae NguyenMarketing Executiveshae@analyticavietnam-exhibitions.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Trade Development Council (HKTDC) welcomes the 2026–27 Budget delivered this morning by the Financial Secretary of the Hong Kong Special Administrative Region (HKSAR), Paul Chan. The Budget reflects the HKSAR Government’s determination and proactive approach to growing the economy, driving development and improving people’s livelihoods. It focuses on strengthening Hong Kong’s status as an international centre for financial, trade, shipping and I&T, while accelerating new industrialisation and digital transformation.The Budget also supports enterprises in integrating into the country’s overall development and seizing opportunities under the 15th Five-Year Plan. This includes continuously improving the business environment, promoting artificial intelligence and green sustainable development, as well as implementing various measures to consolidate Hong Kong’s unique advantages in connecting the Chinese Mainland and the world.Prof Frederick Ma, Chairman of the HKTDC, said: “The HKTDC welcomes the forward-looking measures in the Budget, including the announcement of the city’s first five-year plan and injecting HK$200 million into the BUD Fund. These initiatives demonstrate the HKSAR Government’s commitment to supporting Hong Kong SMEs and facilitating economic transformation and high-quality development. We will actively align with the Government’s policy direction, implement the national 15th Five-Year Plan, and support Hong Kong in consolidating and enhancing its position as an international financial, shipping and trading centre, while establishing the city as an international hub for I&T and high calibre talents.We will also extend our global business network, further deepen our ties with the ASEAN and Middle Eastern markets and explore more emerging markets. These efforts will further enhance Hong Kong’s pivotal role in the Belt and Road Initiative.”Prof Ma added: “As a superconnector and super value-adder, Hong Kong enjoys the unique edge of linking the mainland and global markets. We successfully bring in international capital, technology, talents and advanced management expertise, helping mainland and local enterprises upgrade and innovate, while supporting mainland companies to go global via Hong Kong’s professional services platform.“As a core member of the GoGlobal Task Force, the HKTDC will further leverage its network of 51 offices worldwide to help businesses explore global markets, diversify risks and achieve growth. We will continue to provide value-added services to Hong Kong enterprises, especially SMEs, empowering them to capitalise on e-commerce opportunities, drive their digital transformation and enhance their competitiveness.”Comprehensive Go-Global Support ServicesThe HKTDC will strengthen its diverse business platforms, including international exhibitions, conferences, business matching, market intelligence and e-commerce support, offering one-stop comprehensive go global assistance, covering brand promotion, supply chain management, professional services matching and risk management.The HKTDC will roll out more concrete measures and support programmes to help Hong Kong and mainland enterprises capitalise on national development strategies and global market opportunities and expand their international business in a sustainable manner.Strengthening I&T ecosystem to help enterprises capture opportunitiesThe Budget introduced a range of measures to promote Hong Kong’s development as an international I&T hub. The HKTDC will continue to actively support the HKSAR Government by integrating I&T elements into its exhibitions, conferences and events. These platforms will help promote Hong Kong’s I&T strengths and ecosystem advantages to mainland and overseas markets, foster cross-industry and cross-regional collaboration and incorporate IP elements to enhance overall competitiveness and effectively protect innovation outcomes.As the flagship event of the Business of Innovation and Technology Week (BIT Week) jointly organised by the Innovation, Technology and Industry Bureau of the HKSAR Government and the HKTDC, InnoEX will once again take place in April to showcase cutting-edge technologies and global innovations, as well as accelerate technology commercialisation and achieve sustainable growth.The HKTDC will continue to leverage Hong Kong’s unique advantages as a global business hub, using its flagship events, efficient business matching and professional service connections to support businesses expand internationally.The Budget also notes that the Asian Financial Forum (AFF) will celebrate its 20th anniversary next year. The HKTDC will work closely with the HKSAR Government to further strengthen AFF’s focus on finance empowering business (Finance +), by leveraging on the Global Business Summit, to enable the financial sector to better serve the real economy and industries with a competitive edge.Media enquiriesHKTDC’s Communications & Public Affairs Department:Agnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgSam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain. Building on the momentum from MWC 2025 — the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Appendix: Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order)No.Name of Tech Company / InstitutionCategoryMWC 2026 – Booth 6E44 at Hall 61Entoptica LimitedDevices & Systems2eSIXConnectivity3Faraconix Technologies Co., Ltd.Connectivity4FreightAmigo Services LimitedDigital Transformation5Glassdio Scientific Company LimitedConnectivity6Harvest Elite International LimitedDigital Transformation7HongKong Umedia LimitedDevices & Systems8iASPEC Services LimitedDigital Transformation9InvestHKEcosystem Partners10Robocore Technology LimitedDevices & Systems11Shannon & Turing Technology LimitedConnectivity12The Hong Kong Polytechnic UniversityEcosystem Partners13Xeroptix TechnologyDevices & Systems4YFN 2026 – Booth 8.1B31 at Hall 8.114AIGM LimitedDigital Transformation15BWSea Technology (HK) Co., LimitedDigital Transformation16Cresento LimitedDevices & Systems17GoGoChart Technology LimitedDigital Transformation18HairCoSys LimitedDevices & Systems19KNQ Technology LimitedDigital Transformation20Solos Technology LimitedDevices & Systems21Vista Innotech LimitedDevices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel: +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 今日，市场关注到首程控股（00697.HK）股价出现一定波动，叠加个别股份变动安排，引发部分投资者讨论。综合公司近期公告、公开行情数据及市场结构变化情况来看，相关波动更多体现为阶段性资金博弈。在资本结构持续优化、产业主线逻辑清晰的背景下，公司基本面未发生实质性变化。市场人士透露，在近期市场调整过程中，部分国际长线资金通过协议及大宗方式完成战略性布局，实现了筹码结构的有序转换。相关观点认为，这种"短期筹码向长期资本转移"的过程，有助于平滑阶段性流动性波动，同时提升股东结构的稳定性与质量。从资金属性看，长线资本的进入往往意味着对公司中长期成长路径与价值兑现能力的认可，为后续估值修复奠定更加坚实的资金基础。从资本市场运行规律来看，当企业战略转型逐步进入成果兑现阶段时，股东结构的优化与再平衡往往同步发生。本轮结构调整所释放的核心信号在于，国际资金正以更为积极的姿态参与公司成长进程，认可其由传统资产管理平台向"硬科技产业生态构建者"升级的战略方向。这种资本与产业逻辑的共振，有助于强化市场对公司长期价值的认知与定价信心。外资机构的逆势买入，其逻辑支撑源于首程控股基本面的深刻蜕变。公司正从传统的资产管理平台，成功向"产业生态构建者"转型。通过独特的"资本+场景+运营"三维模式，首程控股已构建起闭环生态，特别是在机器人赛道的前瞻性布局，已使其成为港股硬科技投资的标杆。2026年被市场普遍视为具身智能与人形机器人商业化加速落地的重要时间窗口。首程控股前期在机器人赛道的系统性布局，正在进入集中收获期，机器人赛道整体投资回报表现亮眼：核心项目实现高溢价： 依托对自变量科技、宇树科技等领军企业的早期重仓已实现显著账面增值，随着宇树科技等明星项目正式开启IPO冲刺，首程控股持有的股权将迎来从"账面浮盈"向"现金分红"的实质性跨越，持续增厚上市公司利润。此外，值得关注的是，在2026年马年央视春晚舞台上，宇树科技、银河通用、松延动力等机器人企业集体亮相，展示了具身智能技术在复杂动作控制与人机交互方面的突破。这不仅强化了公众认知，也标志着相关企业已进入规模化应用前夜。作为上述企业的重要早期布局方，首程控股间接受益于产业热度与商业化进程提速带来的估值重估。市场分析人士表示，今日的市场交易将促使公司股东结构更趋多元化。国际长线资金的进入，一方面提升了股票的全球流动性基础与治理透明度预期，另一方面也为未来产业扩张提供更广泛的资源协同空间。从市场经验看，当企业基本面处于上行周期且结构性不确定性逐步消除时，股东结构的优化往往成为估值修复的重要触发因素。分析人士指出，本轮筹码调整本质上是资本结构的战略再平衡，为公司进入价值兑现周期扫清短期供给压力。综合来看，首程控股当前处于三重拐点叠加阶段，首先是产业拐点—具身智能与机器人商业化加速；其次是资本拐点—投资项目进入集中兑现期；再次是结构拐点—国际长线资本入场优化股东结构。在国际资金认可与产业价值红利共振之下，公司估值逻辑正从"传统资管估值框架"向"硬科技产业平台估值框架"切换。随着产业落地与资本回报逐步兑现，市场对于首程控股作为"智能时代产业基础设施构建者"的认知将进一步强化，其长期价值重塑进程或已进入实质性阶段。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – Shoucheng Holdings Ltd. (00697.HK) drew market attention on Tuesday after its share price experienced volatility alongside certain shareholding adjustments, prompting discussion among investors. A review of the company’s recent disclosures, publicly available trading data and evolving market structure suggests the movement largely reflects short-term capital repositioning rather than any change in fundamentals.Market participants indicated that during the recent market pullback, several international long-only investors executed strategic allocations through block trades and negotiated transactions, facilitating an orderly transition in the company’s shareholder base. Observers said the shift — characterized by a rotation from short-term trading positions to longer-duration institutional capital — could help smooth liquidity fluctuations while enhancing the stability and quality of the shareholder structure.From a capital-markets perspective, the entry of long-term funds typically signals recognition of a company’s medium- to long-term growth trajectory and value realization capacity. Such positioning is widely viewed as laying a firmer foundation for future valuation normalization.Historically, shareholder base optimization and rebalancing often coincide with the stage at which a company’s strategic transformation begins to translate into tangible results. The latest restructuring underscores a more proactive stance by international capital in participating in Shoucheng’s growth story, endorsing its strategic shift from a traditional asset-management platform to a builder of hard-technology industrial ecosystems. The resonance between capital flows and industrial logic is expected to reinforce market confidence in the company’s long-term value proposition.Foreign institutional buying during periods of market weakness reflects confidence in what analysts describe as a structural transformation of Shoucheng’s fundamentals. The company has transitioned from a conventional asset-management model into what it terms an “industrial ecosystem builder.” Through a differentiated “capital + scenario + operations” framework, Shoucheng has established a closed-loop ecosystem, particularly in the robotics sector, where its forward-looking investments have positioned it as a bellwether for hard-technology exposure in Hong Kong equities.The year 2026 is widely regarded by the market as a pivotal window for the accelerated commercialization of embodied artificial intelligence and humanoid robotics. Shoucheng’s systematic early-stage positioning across the robotics value chain is now entering a concentrated realization phase, with portfolio returns demonstrating notable strength.Core projects have generated substantial premiums. Early and concentrated investments in leading companies such as Zibianliang Technology and Unitree Robotics have delivered significant mark-to-market gains. As high-profile holdings including Unitree advance toward initial public offerings, Shoucheng’s equity stakes are poised to transition from unrealized book gains to realized returns and dividend contributions, providing tangible earnings accretion at the listed-company level.Further attention has focused on the high-profile appearance of robotics firms including Unitree Robotics, Galaxy General Robotics and Songyan Dynamics at the 2026 Lunar New Year Gala broadcast by China Central Television, the Year of the Horse edition. Their demonstrations showcased breakthroughs in embodied intelligence, complex motion control and human-machine interaction. The visibility not only strengthened public awareness but also signaled that large-scale commercial deployment may be imminent. As an important early-stage investor in these enterprises, Shoucheng stands to benefit indirectly from both heightened sector visibility and an accelerated commercialization cycle, potentially catalyzing valuation re-rating.Analysts said Tuesday’s trading activity is likely to result in a more diversified shareholder mix. The participation of long-duration international capital may enhance the stock’s global liquidity profile and governance transparency expectations, while also broadening the company’s access to cross-border industrial and strategic resources to support future expansion.Market experience suggests that when a company’s fundamentals enter an upward cycle and structural uncertainties gradually dissipate, shareholder optimization can serve as a catalyst for valuation recovery. According to analysts, the latest rotation in holdings represents a strategic rebalancing of the capital structure, easing short-term supply pressure as the company approaches a value-realization phase.Taken together, Shoucheng appears to be navigating a convergence of three inflection points. First is an industrial inflection, as embodied AI and robotics commercialization accelerate. Second is a capital inflection, with investment projects entering a concentrated realization period. Third is a structural inflection, marked by the entry of long-term international capital and the optimization of the shareholder base.Amid the alignment of global capital endorsement and industrial value dividends, the company’s valuation framework is shifting from that of a traditional asset manager toward that of a hard-technology industrial platform. As industrial deployment advances and investment returns crystallize, market recognition of Shoucheng’s role as an infrastructure builder for the intelligent era may deepen, suggesting that the process of long-term value redefinition has entered a substantive phase. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
深圳, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）已于2026年2月24日获得中国国家药品监督管理局（NMPA）受理磷酸芦可替尼乳膏（"产品"）轻中度特应性皮炎（"AD"）的新药上市许可申请（NDA）。产品拟用于其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。且该项NDA因"符合儿童生理特征的儿童用药品新品种、剂型和规格"，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。特应性皮炎III期临床数据亮眼，优先审评加速上市磷酸芦可替尼乳膏已于2026年1月获得NMPA批准上市，成为中国批准的首款且唯一用于白癜风治疗的靶向药。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。磷酸芦可替尼乳膏已在轻中度AD的一项随机、双盲、安慰剂对照中国三期药物临床研究取得积极结果：- 疗效优异：产品成功达到主要终点，即使用产品治疗8周，达到研究者整体评估（IGA）评分为0或1分，且较基线改善≥2分的受试者比例，显著高于安慰剂（63.0% vs 9.2%，P<0.001）。关键次要终点，磷酸芦可替尼乳膏治疗8周，达到湿疹面积及严重程度指数评分较基线至少改善75%（EASI 75）的受试者比例亦显著优于安慰剂（78.0% vs 15.4%，P<0.001）。- 安全性良好：治疗期出现的不良事件（TEAE）的严重程度大多数为轻度或中度，未发生导致研究药物用药终止的TEAE，整体安全耐受性良好。此外，该项NDA已获批纳入优先审评品种名单。根据NMPA相关规定，适用优先审评审批程序的上市注册申请的审评时限由常规程序的200日大幅缩短为130日，审评时限将得到显著缩短，这将有望加速磷酸芦可替尼乳膏AD适应症的上市进程，早日惠及广大患者。构建特应性皮炎综合方案，强化皮肤领域竞争实力AD是一种慢性、复发性、炎症性的皮肤疾病，临床主要表现为皮肤干燥、慢性湿疹样皮损和明显瘙痒，可能严重影响患者的生活质量。据估算，2024年中国特应性皮炎患者超过5,400万人，基于SCORAD评分，轻中度特应性皮炎的占比为98%，即超过5,250万患者[1]。外用药物是AD最基本的治疗方法。传统外用药物如外用糖皮质激素（TCS）及外用钙调神经磷酸酶抑制剂（TCIs）有长期用药的不良反应或疗效有限的临床痛点，临床亟需新的治疗选择。德镁医药已针对AD构建了全方位的"治疗+护理"综合解决方案，除局部外用制剂-磷酸芦可替尼乳膏（轻中度AD）外，还包括注射用生物制剂-柯美奇拜单抗注射液-MG-K10（中重度AD）、口服小分子靶向药-CMS-D001（中重度AD）、日常修护-禾零舒缓产品系列，满足AD患者从治疗到日常护理的管理需求。同时，此次增加AD适应症NDA获受理，将进一步强化德镁医药在皮肤治疗领域的战略布局，并与现有处于商业化阶段的创新药益路取（替瑞奇珠单抗注射液）、独家药喜辽妥（多磺酸粘多糖乳膏），以及系列在研创新药和皮肤学级护肤品等在专家网络与市场资源等方面产生协同，提升德镁医药在皮肤健康领域的市场竞争力与品牌影响力。关于磷酸芦可替尼乳膏的更多信息磷酸芦可替尼乳膏（Opzelura(R)）是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏。在中国，磷酸芦可替尼乳膏获批用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风。在美国，磷酸芦可替尼乳膏是经美国食品和药物管理局（FDA）批准的首款局部JAK抑制剂，可用于局部治疗12岁及以上患者的非节段型白癜风；及其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗[2]。在欧洲，磷酸芦可替尼乳膏被批准用于治疗成年及12岁及以上青少年面部受累的非节段型白癜风[3]。康哲药业于2022年12月2日，通过德镁医药的附属公司与Incyte就磷酸芦可替尼乳膏订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一囯（"区域"）研发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将磷酸芦可替尼乳膏除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。Incyte拥有磷酸芦可替尼乳膏全球开发和商业化权利，在美国及欧洲以Opzelura(R)的名称销售。Opzelura(R)和Opzelura(R)标识是Incyte的注册商标。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.数据来自灼识咨询报告2.FDA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3.EMA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和-医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月24日，康希诺生物（688185.SH/06185.HK）宣布，公司自主研发的ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）——曼海欣(R)扩大适用人群的补充申请已正式获得国家药品监督管理局批准。此次获批后，曼海欣(R)适用于3月龄至6周岁（83月龄）的婴幼儿及儿童，用于预防由A、C、Y、W135群脑膜炎奈瑟菌引起的流行性脑脊髓膜炎（以下简称"流脑"）。此次曼海欣(R)扩龄获批，具有重要的公共卫生和商业发展意义。一方面，在我国现行免疫规划程序中，6岁是入学前流脑疫苗接种"最后一针"的重要节点，长期以来，国内针对3岁以上儿童的多价流脑结合疫苗选择相对有限。曼海欣(R)此次扩龄获批，为学龄期儿童提供了四价流脑多糖结合疫苗接种选择，有助于填补儿童流脑防控在关键年龄阶段的保护空白，进一步完善我国流脑免疫屏障。另一方面，适用人群范围的扩大，将有助于曼海欣(R)进一步释放产品潜力，提升商业化空间，并为该产品在国际市场的推广与布局奠定更为坚实的基础。值得一提的是，康希诺生物日前已发布2025年度业绩预告，全年营收预计10.4–10.8亿元，同比增长22.88%-27.61%；归母净利润预计2450万–2900万元，将实现扭亏为盈。同时，公告明确指出，"公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗曼海欣(R)收入保持持续增长"。这也意味着康希诺生物已进入创新疫苗商业化收获期。依托独家技术平台、领先优势及加速的国际化布局，曼海欣(R)扩龄不仅巩固了市场竞争力，也为康希诺生物的可持续增长注入新的动力。随着产品覆盖和国际拓展的推进，公司长期价值将开启更广阔的发展空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: (852) 5983-9260Phone: (86)1392-3804-279Intelligent Joy Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月22日, 纳斯达克上市公司迦里仕人才集团有限公司（Galaxy Payroll Group Limited，NASDAQ: GLXG，以下简称“迦里仕人才”）宣布，已与耐吉中国控股香港有限公司澳门分公司（NIKE China Holding HK Limited (Macau Branch)，以下简称“耐吉澳门分公司”）正式续签为期五年的战略合作协议。合作再延五年，服务范围全面覆盖核心HR职能根据协议，双方合作期限自2025年12月1日起至2030年11月30日止。在此期间，迦里仕人才将继续为耐吉澳门分公司提供涵盖本地薪资发放、考勤与休假管理、社保及税务合规申报，以及劳动法规与用工政策咨询在内的一站式人力资源外包服务。该合作模式有效支持耐吉澳门分公司聚焦其核心零售与品牌运营，提升整体组织效能。战略续约彰显客户高度信任，强化收入稳定性此次续约不仅是双方合作关系迈入新阶段的重要标志，更体现了国际头部品牌对迦里仕人才专业能力、合规水平及长期服务交付质量的高度认可。中长期合约的签署显著增强了公司未来五年收入的可预测性与现金流稳定性，进一步契合其打造高质量、抗周期业务模型的资本市场战略。本地化能力构筑核心壁垒，服务体系持续进化自2013年成立以来，迦里仕人才始终深耕港澳市场，并逐步拓展跨区域服务能力。公司凭借对香港及澳门劳动法、税务及社保政策的深度掌握，建立起扎实的本地合规能力；同时依托标准化流程与定制化方案相结合的服务体系，确保交付的一致性与可扩展性。其自主开发的薪资与考勤管理平台，在提升运营效率的同时有效保障数据安全与业务连续性，成为吸引并维系跨国企业客户的关键优势。在过往合作中，迦里仕人才已多次协助耐吉澳门分公司应对复杂用工环境下的合规挑战，其解决方案在准确性、响应速度及风险控制方面均获得充分验证，为本次长期续约奠定了坚实基础。展望未来：从服务交付迈向价值共创展望新合作周期，迦里仕人才将在现有服务框架基础上，持续优化薪资管理流程与智能考勤系统，并通过数据整合与定期管理报表，助力客户推进人力资源管理的规范化与数字化转型。双方亦约定保留通过补充协议灵活拓展服务范围的机制，确保合作节奏与客户业务发展动态同步。此次五年期战略合作的续签，不仅是对迦里仕人才专业价值的长期肯定，更是对其商业模式可持续性的有力印证。它将进一步巩固公司在港澳及亚太人力资源外包市场的品牌影响力，并为服务更多跨国零售、体育及消费品牌提供可复制的标杆案例。在全球企业日益重视合规效率、成本优化与组织韧性的背景下，迦里仕人才正凭借其深厚的本地化经验、稳健的服务体系与高粘性的优质客户基础，稳步构建长期增长动能。公司管理层表示：“我们将继续以服务能力为核心驱动力，深化与现有优质客户的战略合作，同时积极拓展更多具有长期价值的跨国及区域性企业客户，持续为股东创造稳健、可持续的回报。” Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2月23日，由上海实业（集团）有限公司（以下简称"上实集团"）与国泰海通证券股份有限公司（以下简称"国泰海通"）联合发起设立的沪港新兴产业基石基金（以下简称"基石基金"）正式启航，进入实质投资阶段。作为全国首支、上海市级市场化运作的证券类港股基石基金，基金目标总规模30亿港元，首期规模10亿港元，将聚焦集成电路、生物医药、人工智能上海三大先导产业，专项支持优质企业赴港上市，深化沪港金融与产业协同。服务上海战略，强化沪港联动上海市政府和上海市国资委指导设立的基石基金，是上海国资服务上海科技创新中心建设、推动重点产业高质量发展的重要举措，将紧密围绕上海前瞻的集成电路、生物医药、人工智能三大先导产业进行战略布局，通过资本市场赋能，加速本地创新企业国际化进程。同时，基金也将充分发挥香港作为国际金融中心的枢纽功能，构建"上海产业+香港资本"的高效联通机制，促进两地金融资源互补与市场互联，打造沪港合作新标杆。创新"双管理人"架构，汇聚两地专业力量基石基金在治理模式上采用创新的"双管理人"架构，由上实集团在港金融投资业务平台上实资本（香港）投资管理有限公司，和国泰海通在港资产管理平台海通国际资产管理有限公司共同担任基金管理人，并由沪港两地协同运营。这一合作架构充分融合了上实集团作为上海在港窗口企业的产业资源与香港本地的运营优势，及国泰海通在全球资本市场和跨境资产管理方面的专业能力，实现"产业+金融"、"上海+香港"的双重优势互补。通过建立完善的投资决策机制与风险控制体系，该架构既确保了基金运作符合国际标准，又保持了与本土产业生态的深度链接，为基金的长期稳健运作奠定了坚实基础。多元化投资策略，专注长期价值基石基金坚持市场化、专业化、国际化运作原则，以产业、金融双重视角，构建覆盖企业全生命周期的投资与赋能体系。通过灵活的多元化策略组合与深度投后服务，系统性支持上海三大先导产业优质企业的业务发展与价值实现。基石基金在重点参与上海三大先导产业优质企业赴港IPO的基石投资之外，还可以参与港股IPO锚定和已上市港股的配售投资，通过无锁定期策略保持基金的流动性，以保证基金投资收益；在市场大幅下跌时，也可通过二级市场方式，增持价值低估的优质公司股票；同时跟进优秀企业再融资及并购重组，助力可持续发展。基石基金将严格遵循"好赛道、好公司、好价格"的遴选标准，重点投向具备核心技术、高成长性和稳健现金流的行业领军企业。强化上海国资在港功能，构建跨境投资新平台基石基金是上实集团和国泰海通强化在港服务功能、完善跨境投资布局的关键举措之一。基石基金不仅进一步完善上海国资基金矩阵，填补国资基金在港股IPO及二级市场策略的空白，服务上海企业赴港上市"最后一公里"融资需求，助力构建"早期投资—成长期融资—公开市场上市"的完整产业投资生态；更通过上实集团和国泰海通的深度合作，强强联手、协作共赢，系统提升跨境合规、资产配置与复杂交易设计能力，进一步增强上海国资服务上海乃至国家战略的综合实力。展望：链接国际资本，赋能创新未来在全球科技创新竞争日益激烈的背景下，沪港新兴产业基石基金的实质启动，标志着上海在对接国际资本市场、服务本土创新方面迈出系统性的一步。在人民币国际化和"惠港五条"等政策红利支持下，基石基金将成为连接内地产业资本与国际金融资源的重要纽带。未来，基石基金将积极把握人民币国际化与金融市场双向开放机遇，持续促进国际资本投资上海核心产业，为上海三大先导产业企业提供全方位的资本服务，助力更多硬科技企业走向世界，为沪港融合与高质量发展贡献力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
